Title
Category
Credits
Event date
Cost
  • 0.75 NCPD/CNE
  • 1.00 Participation
$0.00
Webinar InformationWebinar DescriptionIn this course, Mary Dunn, MSN, RN, NP-C, OCN, will provide a general overview of Prostate Cancer. The audience will learn about basic pathophysiology and epidemiology as it relates to both local and advanced disease.
  • 0.75 NCPD/CNE
  • 1.00 Participation
$0.00
Webinar InformationWebinar DescriptionIn this course, Mary Dunn, MSN, RN, NP-C, OCN, will go into more detail for treatment options and considerations for treating localized prostate cancer and the management of side effects.
  • 0.75 NCPD/CNE
  • 1.00 Participation
$0.00
Webinar InformationWebinar DescriptionIn this course, Mary Dunn, MSN, RN, NP-C, OCN, will discuss the different treatment options for advanced prostate cancer as well as considerations for management side effects and maximizing a survivor’s quality of life.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Lauren M.B. Burke, MD, and Katrina A. McGinty, MD, provide an overview of different imaging modalities for imaging the abdomen, as well as some of their common indications and patient-specific limitations. They will also discuss an overview of commonly used imaging modalities with an emphasis on understanding different modalities' strengths and limitations. The goal is to provide instruction on deciding when different imaging modalities and tests are appropriate for different pathologies.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Marc Bjurlin, DO, MSc, FACOS, gives a contemporary overview of prostate cancer screening with a focus on prostate cancer in men in North Carolina.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Hung-Jui Tan, MD, MSHPM, will review recent practice-changing research and new management recommendations for patients with prostate, kidney, bladder, and testicular cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Mark Woodcock gives a broad overview of the multidisciplinary approaches for the treatment of soft tissue sarcomas in adults, and detailed updates in management with systemic therapies. Specific attention is paid to sarcoma sub-types which may warrant special considerations.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 CTR Category A
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Natalie Grover, MD, will review some of the recent advances in the treatment of lymphoma, including the incorporation of novel targeted agents in the frontline treatment of diffuse large B cell lymphoma and Hodgkin lymphoma, the use of CAR-T cell therapy in second-line treatment in diffuse large B cell lymphoma, and recently approved drugs by the FDA for lymphoma.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Ashley Weiner, MD, PhD, presents on the role of radiotherapy for small-cell lung cancer. She provides overview of radiation oncology, and a walk through a patient's pathway from initial consultation with a radiation oncologist to treatment and follow-up. Finally, she reviews the indications for, logistics of, and side effects of radiation for the treatment of small cell lung cancer (limited and extensive stage).
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Jethro Hu, MD, will review the rationale and current evidence supporting the potential role of a ketogenic diet for brain tumor patients, focusing on a recently completed phase 1 safety and feasibility trial.

Pages